Pfizer Inc

Insider confidence at Pfizer: Senior VP Dennis P. keeps a steady stake while others buy phantom stock, signaling long‑term optimism for the pharma giant.

Pfizer insider confidence: senior execs hold 45K shares and SARs, boosting long‑term growth signals amid market volatility.

Pfizer insider Boulla’s recent phantom‑stock purchase signals confidence in the company’s near‑term earnings and long‑term pipeline, reinforcing its bullish outlook.

Pfizer CEO Albert Bourla buys more phantom stock, signaling confidence in the drugmaker’s upside as shares near a 52‑week high.

Pfizer insiders, including Quincey James, keep buying phantom stock units, signaling long‑term confidence in the company’s oncology and immunology growth.

Pfizer board member Buckley Mortimer’s 1,386 phantom‑stock unit purchase signals strong insider confidence, aligning long‑term goals with shareholder value.

Insider buying at Pfizer signals confidence in its GLP‑1 & oncology pipeline – senior leaders’ RSU purchases and sales suggest long‑term upside.

Pfizer insider selling rises as Jennifer Damico sells shares, revealing liquidity moves and potential leadership shift—what investors should watch.

Pfizer insider moves: R&D president sells shares for taxes, CEO buys phantom units—confidence in pipeline but cautious market outlook.

Albert Bourla’s recent phantom‑stock purchase shows steady confidence in Pfizer’s pipeline and long‑term value creation.